Komori
Other Disclosures4884Kringle Pharma,Inc.Pharmaceuticals

Notice of the publication in an international academic journal of a paper on traumatic cervical spinal cord injury by the North American Spinal Cord Injury Consortium, which we support

A paper by the North American Spinal Cord Injury Consortium, which is supported by our company, was published in the online edition of the international academic journal Spinal Cord. The paper examines the recovery goals considered important by people with traumatic cervical spinal cord injury and how clinically meaningful improvement should be assessed.

Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

Oremepermin alfa (recombinant human HGF protein)
Applicable field (uses covered by this announcement)

Traumatic cervical spinal cord injury; treatment research and clinical trials in the acute phase of spinal cord injury

What the company reported numerically
Quantitative Effects

The paper showed that even small functional improvements can lead to greater independence, reduced caregiving burdens and improved quality of life (QOL).

Relationship between the counterparty and the company
Kringle Pharma,Inc.4884
Relationship with the Company

Consortium supported by our company

CounterpartyNorth American Spinal Cord Injury Consortium (NASCIC)

A nonprofit organization that brings together people with spinal cord injuries, healthcare professionals, researchers and related organizations to improve the quality of life of people with spinal cord injuries and advance healthcare and research. It engages in policy advocacy, education and awareness activities, and research support.

Registration number and expiry date

DOI: https://doi.org/10.1038/s41393-026-01244-8

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

National Spinal Cord Injury Statistical Center, Traumatic Spinal Cord Injury Facts and Figures at a Glance, 2026

Announced details
ItemDetails
Names of Products / Services CoveredOremepermin alfa (recombinant human HGF protein)
CounterpartyNorth American Spinal Cord Injury Consortium (NASCIC)
Counterparty overviewA nonprofit organization that brings together people with spinal cord injuries, healthcare professionals, researchers and related organizations to improve the quality of life of people with spinal cord injuries and advance healthcare and research. It engages in policy advocacy, education and awareness activities, and research support.
Relationship with the CompanyConsortium supported by our company
Applicable areaTraumatic cervical spinal cord injury; treatment research and clinical trials in the acute phase of spinal cord injury
Registration number and expiry dateDOI: https://doi.org/10.1038/s41393-026-01244-8
Quantitative EffectsThe paper showed that even small functional improvements can lead to greater independence, reduced caregiving burdens and improved quality of life (QOL).
SourceNational Spinal Cord Injury Statistical Center, Traumatic Spinal Cord Injury Facts and Figures at a Glance, 2026
Items this document does not state (10)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocationLocation scaleUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To promote research and development that prioritizes the perspectives of people with lived experience and to realize treatments that address the unmet medical needs of people with spinal cord injuries.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the publication in an international academic journal of a paper on traumatic cervical spinal cord injury by the North American Spinal Cord Injury Consortium, which we support | Kringle Pharma,Inc. (4884) timely disclosure | Komori